Efficacy and safety of cilostazol in decreasing progression of cerebral white matter hyperintensities—A randomized controlled trial

Efficacy and safety of cilostazol in decreasing progression of cerebral white matter hyperintensities—A randomized controlled trial

Abstract Introduction Cerebral small vessel disease (SVD) is an important cause of dementia that lacks effective treatment. We evaluated the efficacy and safety of cilostazol, an antiplatelet agent with potential neurovascular protective effects, in slowing the progression of white matter hyperinten...

Full description

Bibliographic Details
Main Authors: Bonaventure Y. M. Ip, Bonnie Y. K. Lam, Vincent M. H. Hui, Lisa W. C. Au, Mandy W. T. Liu, Lin Shi, Vivian W. Y. Lee, Winnie C. W. Chu, Thomas W. Leung, Ho Ko, Vincent C. T. Mok
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
brain
cerebral small vessel diseases
cilostazol
clinical trials
dementia
intention‐to‐treat analysis
Online Access:https://doi.org/10.1002/trc2.12369

Internet

https://doi.org/10.1002/trc2.12369

Similar Items